Do you want to read an article? Please log in or register.
Brief Report: Phase II Clinical Trial of Atezolizumab in Advanced Nonsmall Cell Lung Cancer Patients Previously Treated With PD-1-Directed Therapy
Lung Cancer
Related content
Lung Cancer
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial
Nat Commun
Zeng L, Ruan Z, Yan H, Qin H, Zeng Z, Zou C, Huang Z, Jiang W, Dai J, Xu S, Song L, Chen Y, Zhang Y, Zeng F, Wei S, Chen S, Liu L, Xiong Y, Wang Z, Deng J, Zhang X, Sun Y, Yang D, Zhou C, Yang H, Li Y, Deng L, Xu Q, Fang C, Chen X, Wang J, Li T, Zhang G, Zhou H, Yang N, Zhang Y
doi: 10.1038/s41467-025-67262-x
RECOMMENDED
Lung Cancer
The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Roisman LC, Mann S, Basel A, Marei R, Krayim B, Kornev G, Asna N, Peled N
doi: 10.1016/j.cllc.2025.02.002
Lung Cancer
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials
Lung Cancer
Zhou DD, Lord SJ, Lin FP, Cooper WA, Zaheed M, Simes RJ, John T, Lee CK
doi: 10.1016/j.lungcan.2025.108891
Lung Cancer
Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial
Nat Commun
Yi C, Bian D, Wang J, Hu S, Sun L, Yan Y, Wang S, Shen Z, Yu H, Yang Y, Zhou Y, Liu X, Song N, Zhu Y, Zhao D, Jiang G, Duan L, He W, Xie D, Dai J, Zhang L, Zhang P
doi: 10.1038/s41467-025-57184-z
Lung Cancer
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)
Clin Lung Cancer
Lin JX, Zhou Q, Yan HH, Liu AW, Wu GW, Chu Q, Du YY, Cui JW, Cheng Y, Yang Y, Xu HP, Tu HY, Wu YL, Liu SM
doi: 10.1016/j.cllc.2025.05.014
Lung Cancer
The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study
Lung Cancer
Rolfo C, Gerber DE, Kotecha R, Ward JP, Akerley W, Weiss L, Naveh A, Shapira N, Leal T, Langer CJ, LUNAR study investigators
doi: 10.1016/j.lungcan.2025.108802
Lung Cancer
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial
Clin Lung Cancer
Yang JC, Chen YM, Batra U, Do KH, Sitthideatphaiboon P, Danchaivijitr P, Lee KY, Chindaprasirt J, Yang CT, Chang GC, Charoentum C, Ungtrakul T, Moran JIH, Hartmaier R, Igwegbe I, Gont A, Haskins M, Xu W, Riess JW
doi: 10.1016/j.cllc.2025.10.018
RECOMMENDED
Lung Cancer
The Italian Mauris Phase IIIb Trial of Atezolizumab Plus Carboplatin and Etoposide for Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer: 3-Year End-of-Study Results
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Morgillo F, Del Signore E, Bria E, de Marinis F, Ciardiello F, Garassino MC, Stefani A, Verderame F, Morabito A, Sbrana A, Tonini G, Gilli M, Berardi R, Taveggia PA, Bearz A, Delmonte A, Migliorino MR, Gridelli C, Fadda GM, Iero M, Ardizzoni A
doi: 10.1016/j.cllc.2025.07.003
Lung Cancer
Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States
Adv Ther
Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S
doi: 10.1007/s12325-025-03408-z